Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Table 5

Summary of everolimus pharmacokinetic parameters.

	Median (range)	Mean	SD	CV%
(µghr/L)	421 (257–959)	442	246	55.7%
(µg/L)	7.4 (4–13.8)	9.0	5.2	57.8%
(hr)	1 (0.33–3.08)	1.2	0.9	75.0%
(µg/L)	48.2 (37.8–102.3)	59.4	23.8	40.1%
(hours)	13.8 (10.9–32.4)	16.5	7.5	45.5%

AUC is area under the concentration time curve, is peak plasma concentration, CV% is coefficient of variation, SD is standard deviation, and is time to reach peak plasma concentration.